-
Ligand Partner Viking Therapeutics Announces Closing of Initial Public Offering, 3M Shares @ $8/Shr
Tuesday, May 5, 2015 - 8:13am | 342Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Viking Therapeutics, Inc. (NASDAQ: VKTX) announced that it had closed its initial public offering (the "Viking IPO") of 3,000,000 shares of its common stock at an initial offering price to the public of $8.00 per share. Viking granted the...
-
Pharmacological Advancements in Neuroscience Drug Discovery & Pre-Clinical Studies for Fragile X Syndrome to Identify Drug Candidates for Autism Therapies Lead Biotech Sector Research
Monday, April 20, 2015 - 8:38am | 386In the search for neuroscience drug discovery treatments, Alzheimer's disease and specifically autism drug candidates, a few viable therapeutic approaches have come from research on neurological conditions such as fragile X syndrome. Biotech Companies in focus today are Neurotrope, Inc. (OTC:...
-
Ligand Announces Partner TG Therapeutics Shows Positive Pre-Clinical Data on IRAK4 Compounds
Monday, April 20, 2015 - 7:41am | 255Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the first presentation of preclinical data demonstrating single agent and combination activity of two of TG Therapeutics' IRAK4 inhibitor compounds under development. This pre-clinical...
-
La Jolla Pharmaceutical Company Announces Initiation of Phase 3 Clinical Trial of LJPC-501 in Catecholamine-Resistant Hypotension
Tuesday, March 24, 2015 - 8:00am | 380La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that it has initiated its ATHOS (Angiotensin II for the...
-
JP Morgan Initiates Neurocrine Biosciences With Overweight
Thursday, March 19, 2015 - 9:18am | 63Analysts at JP Morgan initiated coverage on Neurocrine Biosciences Inc. (NASDAQ: NBIX) with a Overweight rating. The target price for Neurocrine Biosciences is set to $54. Neurocrine Biosciences shares have gained 146.60% over the past 52 weeks, while the S&P 500 index has surged 12.15% in the...
-
Benzinga's Top Initiations
Thursday, March 19, 2015 - 8:56am | 165Analysts at JP Morgan initiated coverage on Neurocrine Biosciences Inc. (NASDAQ: NBIX) with a Overweight rating. The target price for Neurocrine Biosciences is set to $54. Neurocrine Biosciences' shares closed at $42.49 yesterday. Analysts at Brean Capital initiated coverage on Melco Crown...
-
Earnings Scheduled For March 19, 2015
Thursday, March 19, 2015 - 5:09am | 623Lennar Corp. (NYSE: LEN) is estimated to report its Q1 earnings at $0.45 per share on revenue of $1.50 billion. Nike, Inc. (NYSE: NKE) is expected to post its Q3 earnings at $0.84 per share on revenue of $7.62 billion. The Cato Corporation (NYSE: CATO) is projected to report its Q4 earnings at $0...
-
Lexicon Pharma Announces Closing of Enrollment in Pivotal Phase 3 Clinical Trial of Telotristat Etiprate
Monday, March 9, 2015 - 8:07am | 252Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on developing breakthrough treatments for human disease, today announced that it has completed enrollment in TELESTAR, its pivotal Phase 3 clinical trial of telotristat etiprate for patients with carcinoid syndrome....
-
Stocks Hitting 52-Week Highs
Wednesday, March 4, 2015 - 11:15am | 148American Eagle Outfitters, Inc. (NYSE: AEO) shares climbed 6.68% to reach a new 52-week high of $15.81 after the company reported stronger-than-expected results for the fourth quarter and issued an upbeat forecast for the first quarter. Burlington Stores, Inc. (NYSE: BURL) shares touched a new...
-
Morning Market Gainers
Wednesday, March 4, 2015 - 10:46am | 348Infosonics Corp. (NASDAQ: IFON) shares surged 61.82% to $2.75. Infosonics reported Q4 earnings of $0.05 per share on revenue of $17.9 million. Novogen Limited(NASDAQ: NVGN) shares jumped 56.29% to $3.93 on positive TRXE-009 results. e-Future Information Technology Inc. (NASDAQ: EFUT) shares...
-
UPDATE: Lexicon Pharmaceuticals Shares Surge On Upbeat Q4 Results
Wednesday, March 4, 2015 - 10:20am | 135Shares of Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) jumped more than 8% in pre-market trading after the company reported stronger-than-expected results for the fourth quarter. Lexicon Pharma posted a quarterly loss of $2.9 million, or $0.00 per share, versus a year-ago net loss of $17.4 million,...
-
Earnings Scheduled For March 4, 2015
Wednesday, March 4, 2015 - 6:09am | 734Abercrombie & Fitch Co. (NYSE: ANF) is expected to report its Q4 earnings at $1.15 per share on revenue of $1.17 billion. American Eagle Outfitters, Inc. (NYSE: AEO) is projected to report its Q4 earnings at $0.34 per share on revenue of $1.06 billion. PetSmart, Inc. (NASDAQ: PETM) is...
-
CRT Capital Initiates Ligand Pharmaceuticals With Buy
Tuesday, March 3, 2015 - 10:24am | 61CRT Capital initiated coverage on Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) with a Buy rating. The target price for Ligand Pharmaceuticals is set to $102. Ligand Pharmaceuticals shares have dropped 13.54% over the past 52 weeks, while the S&P 500 index has surged 12.99% in the same...
-
Benzinga's Top Initiations
Tuesday, March 3, 2015 - 10:07am | 158Analysts at Brean Capital initiated coverage on Syneron Medical Ltd. (NASDAQ: ELOS) with a Buy rating. The target price for Syneron Medical is set to $18. Syneron Medical's shares closed at $11.85 yesterday. Analysts at RBC Capital initiated coverage on Marriott International, Inc. (NASDAQ: MAR)...
-
Morning Market Losers
Monday, February 9, 2015 - 11:00am | 304Speed Commerce, Inc. (NASDAQ: SPDC) shares fell 43.88% to $1.35. Speed Commerce reported a Q3 loss of $0.13 per share on sales of $38.3 million. Fifth Street Finance Corp. (NASDAQ: FSC) shares dropped 15.93% to $7.14. Fifth Street Finance reported a Q1 net loss of $30.7 million. Regulus...